These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 1605655)

  • 1. [A pharmacokinetic study of idarubicin hydrochloride, a new anthracycline anti-tumor drug, in patients with acute leukemia. Idarubicin Study Group].
    Fujita H; Ogawa M; Masaoka T; Yamada K; Kimura K
    Gan To Kagaku Ryoho; 1992 Jun; 19(6):791-8. PubMed ID: 1605655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study of idarubicin hydrochloride in patients with acute leukemia. The Idarubicin Study Group of Japan.
    Tamura K
    Semin Hematol; 1996 Oct; 33(4 Suppl 3):2-11. PubMed ID: 8916310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Childrens Cancer Study Group report.
    Reid JM; Pendergrass TW; Krailo MD; Hammond GD; Ames MM
    Cancer Res; 1990 Oct; 50(20):6525-8. PubMed ID: 2208112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
    Tedeschi A; Montillo M; Strocchi E; Cafro AM; Tresoldi E; Intropido L; Nichelatti M; Marbello L; Baratè C; Camaggi CM; Morra E
    Cancer Chemother Pharmacol; 2007 May; 59(6):771-9. PubMed ID: 17256136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I and clinical pharmacological study of 4-demethoxydaunorubicin (idarubicin) in children with advanced cancer.
    Tan CT; Hancock C; Steinherz P; Bacha DM; Steinherz L; Luks E; Winick N; Meyers P; Mondora A; Dantis E
    Cancer Res; 1987 Jun; 47(11):2990-5. PubMed ID: 3471321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model.
    Berg SL; Reid J; Godwin K; Murry DJ; Poplack DG; Balis FM; Ames MM
    J Pediatr Hematol Oncol; 1999; 21(1):26-30. PubMed ID: 10029808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve.
    Schleyer E; Kühn S; Rührs H; Unterhalt M; Kaufmann CC; Kern W; Braess J; Sträubel G; Hiddemann W
    Leukemia; 1997 Dec; 11 Suppl 5():S15-21. PubMed ID: 9436933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacokinetics of idarubicin.
    Robert J
    Clin Pharmacokinet; 1993 Apr; 24(4):275-88. PubMed ID: 8491056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve.
    Schleyer E; Kühn S; Rührs H; Unterhalt M; Kaufmann CC; Kern W; Braess J; Sträubel G; Hiddemann W
    Leukemia; 1996 Apr; 10(4):707-12. PubMed ID: 8618451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioavailability and pharmacology of oral idarubicin.
    Stewart DJ; Grewaal D; Green RM; Verma S; Maroun JA; Redmond D; Robillard L; Gupta S
    Cancer Chemother Pharmacol; 1991; 27(4):308-14. PubMed ID: 1998987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I clinical trial of orally administered 4-demethoxydaunorubicin (idarubicin) with pharmacokinetic and in vitro drug sensitivity testing in children with refractory leukemia.
    Pui CH; de Graaf SS; Dow LW; Rodman JH; Evans WE; Alpert BS; Murphy SB
    Cancer Res; 1988 Sep; 48(18):5348-52. PubMed ID: 3165708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of idarubicin after oral administration in elderly leukemic patients.
    Robert J; Rigal-Huguet F; Huet S; Pris J; Hurteloup P
    Leukemia; 1990 Mar; 4(3):227-9. PubMed ID: 2179640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Idarubicin-related side effects in recipients of T-cell-depleted allogeneic bone marrow transplants are schedule dependent.
    Muus P; Donnelly P; Schattenberg A; Linssen P; Minderman H; Dompeling E; de Witte T
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):47-52. PubMed ID: 8290971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Early phase II study of Idarubicin, a new anthracycline anticancer drug, in acute leukemia. Idarubicin Study Group].
    Ogawa M; Masaoka T; Yamada K; Kimura K
    Gan To Kagaku Ryoho; 1993 May; 20(7):897-906. PubMed ID: 8489296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.
    Plunkett W; Liliemark JO; Adams TM; Nowak B; Estey E; Kantarjian H; Keating MJ
    Cancer Res; 1987 Jun; 47(11):3005-11. PubMed ID: 3471322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients.
    Robert J; Rigal-Huguet F; Hurteloup P
    Hematol Oncol; 1992; 10(2):111-6. PubMed ID: 1592361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 4-demethoxydaunorubicin (idarubicin) in combination with 1-beta-D-arabinofuranosylcytosine in the treatment of relapsed or refractory acute leukemia.
    Berman E; Raymond V; Daghestani A; Arlin ZA; Gee TS; Kempin S; Hancock C; Williams L; Stevens YW; Clarkson BD
    Cancer Res; 1989 Jan; 49(2):477-81. PubMed ID: 2910465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic study of intravenous and oral idarubicin in cancer patients.
    Tamassia V; Pacciarini MA; Moro E; Piazza E; Vago G; Libretti A
    Int J Clin Pharmacol Res; 1987; 7(5):419-26. PubMed ID: 3478310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and tissue distribution of idarubicin and its active metabolite idarubicinol in the rabbit.
    Looby M; Linke R; Weiss M
    Cancer Chemother Pharmacol; 1997; 39(6):554-6. PubMed ID: 9118470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose cytosine arabinoside and idarubicin treatment of chronic myeloid leukemia in myeloid blast crisis.
    Barone S; Baer MR; Sait SN; Lawrence D; Block AW; Wetzler M
    Am J Hematol; 2001 Jun; 67(2):119-24. PubMed ID: 11343384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.